| Abstract|| |
Background: The C677T and A1298C mutations of 5,10-methylenetetrahydrofolate reductase (MTHFR) have been linked with conditions such as depression, bipolar disorder, and schizophrenia, but there are not clear the relationship between MTHFR polymorphisms and obsessive-compulsive disorder (OCD).
Aim: The current study was planned to investigate the link between the MTHFR polymorphisms and OCD in patients to reveal any potential correlations that may be used as a novel marker in diagnosis of people who are in high-risk group of developing OCD.
Materials and Methods: Blood samples from 64 highly characterized symptomatic cases and 64 gender- and age-matched control participants were analyzed for MTHFR C677T and A1298C gene variants. The MTHFR gene polymorphisms were detected through real-time polymerase chain reaction, followed by melting curve analysis. The results were tested with analysis of variance test and the differences with P < 0.05 were reported as statistically significant.
Results: A statistically significant difference in age, education level, and marital status was found in the comparison of all groups in sociodemographic findings (P = 0.004, P = 0.001, and P = 0.001, respectively). A statistically significant difference was found in the comparison of the tic story of early- and late-onset OCD patients (P = 0.002). There was no significant difference in the genotype frequencies and allele distributions of MTHFR polymorphisms between the patients and controls (P > 0.05).
Conclusion: The results suggest that MTHFR polymorphisms are unlikely to play a major role in the pathogenesis of OCD. Further studies are needed in biochemical data on folate metabolism to clarify the effect of the MTHFR polymorphisms in OCD pathophysiology.
Keywords: 5,10-methylenetetrahydrofolate reductase gene polymorphisms, early-onset obsessive-compulsive disorder, folate metabolism, late-onset obsessive-compulsive disorder
|How to cite this article:|
Caliskan M, Orenay-Boyacioglu S, Dondu A. Roles of 5,10-methylenetetrahydrofolate reductase C677T and A1298C polymorphisms in early- and late-onset obsessive-compulsive disorder. Indian J Psychiatry 2019;61:161-6
|How to cite this URL:|
Caliskan M, Orenay-Boyacioglu S, Dondu A. Roles of 5,10-methylenetetrahydrofolate reductase C677T and A1298C polymorphisms in early- and late-onset obsessive-compulsive disorder. Indian J Psychiatry [serial online] 2019 [cited 2021 Jan 16];61:161-6. Available from: https://www.indianjpsychiatry.org/text.asp?2019/61/2/161/253830
| Introduction|| |
5,10-methylenetetrahydrofolate reductase (MTHFR) has key roles in purine and thymidylate biosynthesis through one-carbon metabolism (OCM) in DNA and amino acid methylations, RNA synthesis, and in neurotransmitter formation. MTHFR helps channel OCM units between the DNA cycle and the methylation cycle through the OCM.,, Decrease in MTHFR activity, which is involved in the homocysteine metabolism, affects homocysteine level, an indication of the role of MTHFR in folate metabolism. Mutations in MTHFR are known to cause hyperhomocysteinemia and homocystinuria causing various metabolic problems. The most common polymorphisms occurring in the MTHFR gene are C677T and A1298C. Since MTHFR affects methylation through S-adenosylmethionine, folate distribution, and homocysteine metabolism, genetic defects in MTHFR have a potentially negative and positive regulatory effect on disease risk.,,
Psychiatric symptoms are reported to be related to Vitamin B12, folate, and homocysteine levels.,,,, This fact shows the importance of Vitamin B12, folate, and homocysteine in carbon transfer (methylation), which is essential for the production of serotonin, catecholamines, and other monoamine neurotransmitters. The link between folate deficiency and depressive disorders has been the topic of previous., Later, the focus moved on to the increased folate prevalence and Vitamin B12 deficiency in depressed patients., Observations on the antidepressant effects of folate may support the importance of folate in psychopathology., A few studies showed the effects of excessive OCM in anxiety disorders especially.,,, To the best of our knowledge, there are no studies on the relationship between MTHFR polymorphisms and obsessive-compulsive disorder (OCD). For this reason, we planned this study to investigate if the MTHFR polymorphisms in OCD patients are of etiopathogenetic significance and to show the effect of these polymorphisms at early- and late-onset of OCD.
| Materials and Methods|| |
The study sample size was detected by power analysis using G-Power. Patients with a total of 64 OCD diagnoses according to the diagnostic and statistical manual of mental disorders V (DSM-V) diagnostic criteria according to clinical interview scales were divided into two groups according to the age of onset, early and late onset. Beginning age was taken as 15, and those who started after 15 years old were evaluated as late-onset OCD. As a healthy control, 64 patients with no OCD diagnosed and without psychotropic drugs or other medications were included in the study. Familial stories were assessed and those with psychiatric illnesses were recorded. Both healthy controls and OCD patients with schizophrenia, bipolar disorder, or high genetic transmission were not included in the study.
This study was conducted in compliance with the good clinical practice and applicable regulatory procedure required by the Declaration of Helsinki. The study was approved by the Institutional Review Board (IRB) in May 2018. The IRB-approved informed consent forms were obtained from each participant before any study-related procedure.
Sociodemographic form and psychometrics tests
Sociodemographic findings of both groups were obtained by applying a sociodemographic data form. The Yale–Brown Obsessive-Compulsion Scale (Y-BOCS), Hamilton Depression Rating Scale (HAM-D), the Hamilton Anxiety Rating Scale (HAM-A), and the DSM-III-R personality disorders Structured Clinical Interview for DSM-II (SCID-II) were used to measure severity of illness in the OCD group. SCIs were administered for the DSM-IV Axis I Disorders (SCID-I).
Genomic DNA was isolated from peripheral blood samples according to the manufacturer's instructions (Qiagen, Germany). DNA concentration was evaluated by absorbance methodology at 260 nm and DNA purity at 260/280 nm using a NanoDrop 1000 Spectrophotometer V3.7 (Thermo Scientific, USA).
SNPs were determined by real-time PCR using a panel of Light SNP assay from Way2 gene (assays based on Light Cycler HybProbe®). The Light Cycler HybProbe® in the LightSNP assay detects single-base mismatches, thus enabling the analysis of polymorphisms. The amplification process was followed by a melting curve analysis on Light Cycler 2.0 (Roche, Germany). Functional variants mapping in MTHFR gene C677T and A1298C polymorphisms were evaluated.
Amplification values of MTHFR C677T and A1298C genotypes were obtained at 640 nm. Mutant presence was detected at 54.5°C Tm for MTHFR C677T and the wild-type at 63.0°C. For A1298C, the mutant was detected at 58.5°C Tm and the wild-type at 49°C.
Data were analyzed by one-way analysis of variance and Chi-squared tests using SPSS-Windows 15 software package (IBM, Armonk, NY, USA).
| Results|| |
Comparison of sociodemographical and clinical characteristics of the OCD and control groups is summarized in [Table 1]. Statistical differences in age and education level were present between the groups (P = 0.004 and P = 0.001, respectively). A statistically significant difference was also present in marital status between the groups (P = 0.001). There was no significant difference in gender distribution between the groups (P > 0.05). The difference in the tic story between the groups was also statistically significant (P = 0.002). There were no statistically significant differences in obsession type, compulsion type, triggered life story, starting story, HAM-D, HAM-A, Y-BOCS total, Y-BOCS Obsess (Y-BOCS obsessions), and Y-BOCS Comp (Y-BOCS compulsion) between the early- and late-onset OCD patients (P > 0.05) [Table 1].
Based on the genotype analysis, the genotype distribution of MTHFR C677T gene polymorphism was 39% CC, 42% CT, and 19% TT in the OCD group, whereas it was 39% CC, 36% CT, and 25% TT in the control group. For MTHFR A1298C polymorphism, the genotype distribution was 30% AA, 54% AC, and 16% CC in the OCD group and 30% AA, 55% AC, and 15% CC in the control group. Underlying allele frequencies were calculated as 61% C, 39% T for C677T and 62% C, 38% T for A1298C variant in the early-onset OCD group. In the late-onset OCD group, the allele frequencies were 59% C, 41% T for C677T and 55% A, 45% A for A1298C variant. In the control group, the allele frequencies were 57% C, 43%T for C677T and 52% A, 48% A for A1298C variant. No significant difference was found with Chi-squared test between the early- and late-onset OCD group and the control group in terms of the genotype and allele distributions (P > 0.05) [Table 2]. There was also no significant difference between gender, marital status, tic story, obsessions, compulsions, Y-BOCS Total, Y-BOCS Obsess, Y-BOCS Comp, genotype, and allele distributions in the late- and early-onset OCD patients (P > 0.05) [Table 3].
|Table 2: The genotype distributions and allele frequencies for methylenetetrahydrofolate reductase gene polymorphisms in groups|
Click here to view
|Table 3: Comparison of 5,10-methylenetetrahydrofolate reductase gene polymorphisms with demographical and clinical features of groups|
Click here to view
| Discussion|| |
Psychiatric symptoms have been reported to be linked to Vitamin B12, folate, and homocysteine levels. Several studies have shown the effects of excessive carbon metabolism in anxiety disorders, especially OCD. Folate deficiency, high homocysteine levels, impaired methylation, and monoamine metabolism were reported in OCD patients by Atmaca et al. Another study also reported high homocysteine levels and Vitamin B12 deficiency in some OCD patients. One limitation of the current study is that serum levels of Vitamin B12, folate, and homocysteine were not measured in participants.
There are studies in the literature that question the association of OCD with folate, homocysteine, and Vitamin B12, but none with MTHFR gene polymorphisms. Considering the main role of MTHFR in brain function and neurodevelopment,, common genetic variances are reported in psychiatric disorders through family and twin studies.,,, Therefore, this report investigated the potential link between OCD and the MTHFR gene polymorphisms.
Genetic modifications affecting the MTFHR level or function decreases 5-methyltetrahydrofolate level further resulting in increased homocysteine. Major depression was reported to be correlated with both improper folate metabolism and high homocysteine level, which may be due to the MTHFR polymorphisms.,, Moreover, MTHFR C677T and A1298C polymorphisms were linked to major depression and related treatment options.,, Since there are studies showing the relationship between MTHFR gene polymorphisms and major depression in the literature, severe depressive OCD patients having high HAM-D scores were excluded in this study. The average HAM-D score of the OCD participants in our study was 16 with only five participants having a HAM-D score higher than 27. According to these scores, the majority of our patients had mild depressive symptoms and five had moderate depressive symptoms. None of the participants were categorized to have major depressive disorder according to DSM-V diagnostic criteria. The fact that our participants had only mild and moderate depressive symptoms was another limitation of this study.
The link between MTFHR gene polymorphisms and the major psychiatric disorders, including bipolar disorder and schizophrenia, has been exhaustively studied. However, they were mostly inconclusive or reported mixed findings.,,,,,, For example, in a study investigating the MTHFR C677T polymorphism on schizophrenia and affective disorder, it was concluded that the homozygote T allele does not play an important role in the pathogenesis of the diseases.
There are many meta-analyses in the literature that reveal the relationship between psychiatric diseases and MTHFR gene polymorphisms. Two meta-analyses by Lewis et al., on 2427 participants and Muntjewerff et al. on 4986 participants reported an elevated risk for schizophrenia with the TT genotype of MTHFR C677T polymorphism. The link between the MTHFR C677T polymorphism and several psychiatric disorders was also elucidated by two meta-analysis reports by Gilbody et al. and Zintzaras. The former report analyzed a total of 26 studies on schizophrenia (12 studies with over 6100 participants), bipolar disorder (4 studies with over 1600 participants), and unipolar depressive disorder (10 studies with over 11000 participants). The latter report, on the other hand, covered two more articles on the top of what is covered by the former meta-analysis report. Another meta-analysis report examined the links between the MTHFR C677T and A1298C polymorphisms with schizophrenia on over 9500 and 6100 participants, respectively. Furthermore, the links between the MTHFR C677T and A1298C polymorphisms with bipolar disorder were examined on over 2200 and 700 participants, respectively. While the MTHFR C677T polymorphism was examined in all of these meta-analyses, the A1298C was only examined in some of them. One striking result pointed out by Peerbooms et al. in their meta-analysis with over 9600 patients and 19800 control participants was that although the TT genotype was represented in small percentage of the patients, it was significantly related with schizophrenia, bipolar disorder, and unipolar depressive disorder. They also reported that the CC genotype of MTHFR A1298C polymorphism was also rare but significantly related with bipolar disorder not schizophrenia in their meta-analysis with over 3500 patients and 4400 control participants. In the current study, two polymorphisms of MTHFR showed approximately the same genotype profile in comparison of patient and control groups and early-/late-onset OCD groups. In comparison of the patient and control groups, the percentage of CT genotype in MTHFR C677T polymorphism was higher in OCD patients, but no statistical significance was detected in all comparisons.
Demographic differences in the participants may influence how MTHFR gene polymorphisms affect psychiatric disorders. Two studies revealed that demographic background and gender of participants might have close impact on the way MTHFR gene polymorphisms affect psychiatric disorders., In this study, there was no statistically significant difference between the demographic features and MTHFR gene polymorphisms of OCD cases.
| Conclusion|| |
This study was the first to investigate the relationship between early- and late-onset OCD and MTHFR gene polymorphisms, thus reflecting a section of the Turkish population. Our results lacked to show evidence that MTHFR gene polymorphisms play a role in the pathogenesis of OCD in Turkish participants. To clarify the effect of MTHFR C677T and A1298C polymorphisms in the OCD pathophysiology, the number of participants might be increased and biochemical data on folate metabolism might be investigated in the future studies.
Financial support and sponsorship
Conflicts of interest
There are no conflicts of interest.
| References|| |
Sugden C. One-carbon metabolism in psychiatric illness. Nutr Res Rev 2006;19:117-36.
Frankenburg FR. The role of one-carbon metabolism in schizophrenia and depression. Harv Rev Psychiatry 2007;15:146-60.
Krebs MO, Bellon A, Mainguy G, Jay TM, Frieling H. One-carbon metabolism and schizophrenia: Current challenges and future directions. Trends Mol Med 2009;15:562-70.
Laanpere M, Altmäe S, Stavreus-Evers A, Nilsson TK, Yngve A, Salumets A, et al.
Folate-mediated one-carbon metabolism and its effect on female fertility and pregnancy viability. Nutr Rev 2010;68:99-113.
Chen G, Zhang C, Zhang X, Zhu Y, Tang J, Meng Z, et al.
Cloning and expression of 5, 10-methylenetetrahydrofolate reductase (MTHFR) gene. Sci China C Life Sci 1998;41:636-43.
Weisberg IS, Jacques PF, Selhub J, Bostom AG, Chen Z, Curtis Ellison R, et al.
The 1298A-C polymorphism in methylenetetrahydrofolate reductase (MTHFR):In vitro
expression and association with homocysteine. Atherosclerosis 2001;156:409-15.
Födinger M, Hörl WH, Sunder-Plassmann G. Molecular biology of 5,10-methylenetetrahydrofolate reductase. J Nephrol 2000;13:20-33.
Stanger O, Fowler B, Piertzik K, Huemer M, Haschke-Becher E, Semmler A, et al.
Homocysteine, folate and Vitamin B12 in neuropsychiatric diseases: Review and treatment recommendations. Expert Rev Neurother 2009;9:1393-412.
Fafouti M, Paparrigopoulos T, Liappas J, Mantouvalos V, Typaldou R, Christodoulou G, et al.
Mood disorder with mixed features due to Vitamin B12 and folate deficiency. Gen Hosp Psychiatry 2002;24:106-9.
Kale A, Naphade N, Sapkale S, Kamaraju M, Pillai A, Joshi S, et al.
Reduced folic acid, Vitamin B12 and docosahexaenoic acid and increased homocysteine and cortisol in never-medicated schizophrenia patients: Implications for altered one-carbon metabolism. Psychiatry Res 2010;175:47-53.
Kim TH, Moon SW. Serum homocysteine and folate levels in Korean schizophrenic patients. Psychiatry Investig 2011;8:134-40.
Ezzaher A, Mouhamed DH, Mechri A, Omezzine A, Neffati F, Douki W, et al.
Hyperhomocysteinemia in Tunisian bipolar I patients. Psychiatry Clin Neurosci 2011;65:664-71.
Bottiglieri T. Folate, Vitamin B12, and neuropsychiatric disorders. Nutr Rev 1996;54:382-90.
Coppen A, Swade C, Jones SA, Armstrong RA, Blair JA, Leeming RJ, et al.
Depression and tetrahydrobiopterin: The folate connection. J Affect Disord 1989;16:103-7.
Bottiglieri T, Laundy M, Crellin R, Toone BK, Carney MW, Reynolds EH, et al.
Homocysteine, folate, methylation, and monoamine metabolism in depression. J Neurol Neurosurg Psychiatry 2000;69:228-32.
Sachdev PS, Parslow RA, Lux O, Salonikas C, Wen W, Naidoo D, et al.
Relationship of homocysteine, folic acid and Vitamin B12 with depression in a middle-aged community sample. Psychol Med 2005;35:529-38.
Kim JM, Stewart R, Kim SW, Yang SJ, Shin IS, Yoon JS, et al.
Predictive value of folate, Vitamin B12 and homocysteine levels in late-life depression. Br J Psychiatry 2008;192:268-74.
Lindenbaum J, Healton EB, Savage DG, Brust JC, Garrett TJ, Podell ER, et al.
Neuropsychiatric disorders caused by cobalamin deficiency in the absence of anemia or macrocytosis. N Engl J Med 1988;318:1720-8.
Stabler SP, Marcell PD, Podell ER, Allen RH, Savage DG, Lindenbaum J, et al.
Elevation of total homocysteine in the serum of patients with cobalamin or folate deficiency detected by capillary gas chromatography-mass spectrometry. J Clin Invest 1988;81:466-74.
Hermesh H, Weizman A, Shahar A, Munitz H. Vitamin B12 and folic acid serum levels in obsessive compulsive disorder. Acta Psychiatr Scand 1988;78:8-10.
Atmaca M, Tezcan E, Kuloglu M, Kirtas O, Ustundag B. Serum folate and homocysteine levels in patients with obsessive-compulsive disorder. Psychiatry Clin Neurosci 2005;59:616-20.
Levine J, Timinsky I, Vishne T, Dwolatzky T, Roitman S, Kaplan Z, et al.
Elevated serum homocysteine levels in male patients with PTSD. Depress Anxiety 2008;25:E154-7.
Sharma V, Biswas D. Cobalamin deficiency presenting as obsessive compulsive disorder: Case report. Gen Hosp Psychiatry 2012;34:578.e7-8.
Türksoy N, Bilici R, Yalçıner A, Ozdemir YÖ, Ornek I, Tufan AE, et al.
Vitamin B12, folate, and homocysteine levels in patients with obsessive-compulsive disorder. Neuropsychiatr Dis Treat 2014;10:1671-5.
del Río Garcia C, Torres-Sánchez L, Chen J, Schnaas L, Hernández C, Osorio E, et al.
Maternal MTHFR 677C>T genotype and dietary intake of folate and Vitamin B12: Their impact on child neurodevelopment. Nutr Neurosci 2009;12:13-20.
Ueland PM, Hustad S, Schneede J, Refsum H, Vollset SE. Biological and clinical implications of the MTHFR C677T polymorphism. Trends Pharmacol Sci 2001;22:195-201.
Cardno AG, Rijsdijk FV, Sham PC, Murray RM, McGuffin P. A twin study of genetic relationships between psychotic symptoms. Am J Psychiatry 2002;159:539-45.
Lichtenstein P, Yip BH, Björk C, Pawitan Y, Cannon TD, Sullivan PF, et al.
Common genetic determinants of schizophrenia and bipolar disorder in Swedish families: A population-based study. Lancet 2009;373:234-9.
McGuffin P, Rijsdijk F, Andrew M, Sham P, Katz R, Cardno A, et al.
The heritability of bipolar affective disorder and the genetic relationship to unipolar depression. Arch Gen Psychiatry 2003;60:497-502.
Van Snellenberg JX, de Candia T. Meta-analytic evidence for familial coaggregation of schizophrenia and bipolar disorder. Arch Gen Psychiatry 2009;66:748-55.
Fraguas R Jr., Papakostas GI, Mischoulon D, Bottiglieri T, Alpert J, Fava M, et al.
Anger attacks in major depressive disorder and serum levels of homocysteine. Biol Psychiatry 2006;60:270-4.
Gabriela Nielsen M, Congiu C, Bortolomasi M, Bonvicini C, Bignotti S, Abate M, et al.
MTHFR: Genetic variants, expression analysis and COMT interaction in major depressive disorder. J Affect Disord 2015;183:179-86.
Mech AW, Farah A. Correlation of clinical response with homocysteine reduction during therapy with reduced B vitamins in patients with MDD who are positive for MTHFR C677T or A1298C polymorphism: A randomized, double-blind, placebo-controlled study. J Clin Psychiatry 2016;77:668-71.
Reif A, Pfuhlmann B, Lesch KP. Homocysteinemia as well as methylenetetrahydrofolate reductase polymorphism are associated with affective psychoses. Prog Neuropsychopharmacol Biol Psychiatry 2005;29:1162-8.
Evinova A, Babusikova E, Straka S, Ondrejka I, Lehotsky J. Analysis of genetic polymorphisms of brain-derived neurotrophic factor and methylenetetrahydrofolate reductase in depressed patients in a Slovak (Caucasian) population. Gen Physiol Biophys 2012;31:415-22.
Kunugi H, Fukuda R, Hattori M, Kato T, Tatsumi M, Sakai T, et al.
C677T polymorphism in methylenetetrahydrofolate reductase gene and psychoses. Mol Psychiatry 1998;3:435-7.
Feng LG, Song ZW, Xin F, Hu J. Association of plasma homocysteine and methylenetetrahydrofolate reductase C677T gene variant with schizophrenia: A Chinese han population-based case-control study. Psychiatry Res 2009;168:205-8.
Gaysina D, Cohen S, Craddock N, Farmer A, Hoda F, Korszun A, et al.
No association with the 5,10-methylenetetrahydrofolate reductase gene and major depressive disorder: Results of the depression case control (DeCC) study and a meta-analysis. Am J Med Genet B Neuropsychiatr Genet 2008;147B: 699-706.
Gilbody S, Lewis S, Lightfoot T. Methylenetetrahydrofolate reductase (MTHFR) genetic polymorphisms and psychiatric disorders: A HuGE review. Am J Epidemiol 2007;165:1-3.
Pan CC, McQuoid DR, Taylor WD, Payne ME, Ashley-Koch A, Steffens DC, et al.
Association analysis of the COMT/MTHFR genes and geriatric depression: An MRI study of the putamen. Int J Geriatr Psychiatry 2009;24:847-55.
Yu L, Li T, Robertson Z, Dean J, Gu NF, Feng GY, et al.
No association between polymorphisms of methylenetetrahydrofolate reductase gene and schizophrenia in both Chinese and Scottish populations. Mol Psychiatry 2004;9:1063-5.
Yuan YG, Zhang ZJ, Li JJ. Plasma homocysteine but not MTHFR gene polymorphism is associated with geriatric depression in the Chinese population. Acta Neuropsychiatr 2008;20:251-5.
Lewis SJ, Zammit S, Gunnell D, Smith GD. A meta-analysis of the MTHFR C677T polymorphism and schizophrenia risk. Am J Med Genet B Neuropsychiatr Genet 2005;135B: 2-4.
Muntjewerff JW, Kahn RS, Blom HJ, den Heijer M. Homocysteine, methylenetetrahydrofolate reductase and risk of schizophrenia: A meta-analysis. Mol Psychiatry 2006;11:143-9.
Zintzaras E. C677T and A1298C methylenetetrahydrofolate reductase gene polymorphisms in schizophrenia, bipolar disorder and depression: A meta-analysis of genetic association studies. Psychiatr Genet 2006;16:105-15.
Jönsson EG, Larsson K, Vares M, Hansen T, Wang AG, Djurovic S, et al.
Two methylenetetrahydrofolate reductase gene (MTHFR) polymorphisms, schizophrenia and bipolar disorder: An association study. Am J Med Genet B Neuropsychiatr Genet 2008;147B:976-82.
Peerbooms OL, van Os J, Drukker M, Kenis G, Hoogveld L; MTHFR in Psychiatry Group, et al.
Meta-analysis of MTHFR gene variants in schizophrenia, bipolar disorder and unipolar depressive disorder: Evidence for a common genetic vulnerability? Brain Behav Immun 2011;25:1530-43.
Sazci A, Ergül E, Güzelhan Y, Kaya G, Kara I. Methylenetetrahydrofolate reductase gene polymorphisms in patients with schizophrenia. Brain Res Mol Brain Res 2003;117:104-7.
Dr. Seda Orenay-Boyacioglu
Department of Medical Genetics, Faculty of Medicine, Aydin Adnan Menderes University, Aydin
Source of Support: None, Conflict of Interest: None
[Table 1], [Table 2], [Table 3]